Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | FHIT | P49789 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | IRS1 | P35568 | 1/20 | 0.39 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315953 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL299130 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL15945408 | 0.78 | GAA (0.50) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL283280 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL281865 | 0.78 | MAPT (0.43) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL24369643 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL13477788 | 0.76 | GAA (0.44) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL12635484 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL2113638 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPTHPGDSMN1; SMN2GAA | |
| SCHEMBL19558977 | 0.75 | RECQL (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-52048666-A | — | — | None | — | — | JP | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106292-A1 | BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| EP-1869031-B1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | disclosed |
| EP-1869031-B1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | disclosed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | disclosed |
| EP-0532674-A4 | LEUKOTRIENE ANTAGONISTS | — | 1993-04-07 | — | — | EP | disclosed |
| EP-0532674-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5143931-A | 2-Phenyl-2((tetrazolyl or imidazolyl)thio)alkanoic acid derivatives; antiphylactic and bronchodilator agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0296731-B1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5135938-A | Bronchodilator | SMITHKLINE BEECHAM CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1991018889-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
| US-5028601-A | Substituted with an amino thiazole group and a dihydroxy-pyridone group | MEIJI SAIKA KAISHA, LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0296731-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0289002-A2 | Novel cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA LTD. (JP) | 1988-11-02 | — | — | EP | disclosed |
| JP-S5248666-A | PREPARATION OF MERCAPTOTHIAZOLE-CARBOXYLIC ACIDS AND THEIR ESTERS | MEIJI SEIKA KAISHA LTD | 1977-04-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227638-A1 | Novel Pharmaceutical Compounds | LTC4S, LTB4R2, LTB4R | ALDH1A1 1865/4885MAPT 4659/4885HPGD 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.